Abatacept in the long-term treatment of rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 8, Issue 3, 2012, Pages 231-234

  Jani, Meghna ^a   Hyrich, Kimme L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

abatacept; biologics; CTLA 4; efficacy; rheumatoid arthritis; T cell activation

Indexed keywords

ABATACEPT;

BONE RADIOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEART DISEASE; HUMAN; INFECTION; LONG TERM DEPRESSION; LUNG CANCER; LYMPHOMA; MELANOMA; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; TUBERCULOSIS;

EID: 84858415050     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.98     Document Type: Review

References (17)

1. Blumenauer B, Judd M, Wells G et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 3, CD003785 (2002).
2. Blumenauer B, Judd M, Cranney A et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 4, CD004525 (2003).
3. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst. Rev. 3, CD005113 (2005).
4. Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs 23(2), 111-124 (2009).
5. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344(12), 907-916 (2001).
6. Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 37(2), 234-245 (2010).
7. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144(12), 865-876 (2006).
8. Kremer JM, Genant HK, Moreland LW et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 58(4), 953-963 (2008).
9. Genant HK, Peterfy CG, Westhovens R et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann. Rheum. Dis. 67(8), 1084-1089 (2008).
10. Kremer JM, Russell AS, Emery P et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann. Rheum. Dis. 70(10), 1826-1830 (2011).
11. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50(1), 124-131 (2011).
12. Strangfeld A, Eveslage M, Schneider M et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann. Rheumatic Dis. 70(11), 1914-1920 (2011).
13. Singh JA, Christensen R, Wells GA et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med. J. 128(5), 309-310 (2010).
14. Schiff M, Keiserman M, Codding C et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST study. Ann. Rheumatic Dis. 70(11), 2003-2007 (2011).
15. Haggerty HG, Abbott MA, Reilly TP et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J. Rheumatol. 34(12), 2365-2373 (2007).
16. National Institute for Health and Clinical Excellence. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti- rheumatic drugs London: National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 195 (2011).
17. Genovese MC, Covarrubias A, Leon G et al. Subcutaneous abatacept versus intravenous abatacept: a Phase 3b noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 63(10), 2854-2864 (2011).